Blue Venture Fund will exit the cancer diagnostics technology startup in a purchase by another of its investors, Exact Sciences, that could reach $2.15bn.

Molecular diagnostics system provider Exact Sciences agreed yesterday to buy one of its portfolio companies US-based cancer screening technology developer Thrive Earlier Detection, for up to $2.15bn in cash and stock. Exact Sciences will make a $1.7bn upfront payment made up of 65% of stock and 35% of cash while the remaining $450m will be…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.